DALLAS, March 3, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Halozyme Therapeutics Inc. (Nasdaq:HALO). The report includes financial, comparative and investment analysis, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/HALO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Halozyme Therapeutics Inc. (HALO) is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (Matrix) for the endocrinology, oncology, dermatology and drug delivery markets The Company's products are based on the property covering the family of human enzymes known as hyaluronidases. The Company has two marketed products: HYLENEX, a product used as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids, and Cumulase, a product used for in vitro fertilization (IVF). The Company has partnerships with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche, Inc. (Roche), to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets, and with Baxter Healthcare Corp. (Baxter), to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID.
Message Board Search for HALO: http://www.boardcentral.com/boards/HALO
In the report, the analyst notes:
"The net loss for the third quarter of 2009 was $13.9 million, or 16 cents per share, compared with a net loss for the third quarter of 2008 of $10.9 million, or 14 cents per share. Net loss for the nine months ended September 30, 2009 was $45.7 million, or 54 cents per share, compared with a net loss of $31.8 million, or 40 cents per share for the comparable period last year.
"HALO recently announced it plans to report fourth-quarter and annual 2009 financial results on Friday, March 12, 2010, before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PST (11:00 a.m. EST), which will be simultaneously broadcast over the Internet."
To read the entire report visit: http://www.investorsoup.com/lp/HALO
See what investors say about HALO at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.